Previous 10 | Next 10 |
Aytu BioPharma (NASDAQ:AYTU) announced the placement to a healthcare-dedicated institutional investor in an underwritten offering of 3.03M shares of its common stock, pre-funded warrants to purchase up to 3.3M shares of its common stock, and common warrants to purchase up to 6.67M shares of i...
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to a healthcare-dedicated institutional investor in an underwritten offering of 3,030,000 shar...
The European Commission granted orphan designation to Aytu BioPharma's (NASDAQ:AYTU) AR101 (enzastaurin) to treat Ehlers-Danlos Syndrome (EDS),a group of rare inherited connective tissue disorders that includes the severe subtype vascular EDS (VEDS). The designation was backed by positiv...
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European Commission granted orphan designation to AR101 (enzastaurin), a PKCβ inhibitor, for...
Aytu BioScience press release (NASDAQ:AYTU): FQ2 GAAP EPS of -$0.44 beats by $0.14. Revenue of $23.13M (+52.7% Y/Y) misses by $4.07M. For further details see: Aytu BioScience GAAP EPS of -$0.44 beats by $0.14, revenue of $23.13M misses by $4.07M
Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022 Initiation of Randomized, Sham-controlled Study of Healight in Patients with SARS-CoV-2 to Begin Shortly ENGLEWOO...
AAP, ACTG, AESE, OTCPK:AOIFF, DADAASTS, ATHX, AXON, AYTU, BIOC, BITF, CIDM, CMP, OTCQX:CWBHF, CWBR, CWCO, CYBN, DM, DNMR, DRIO, OTCQB:ELTP, ETON, EVFM, GLAD, GNLN, GOEV, IBIO, IDEX, INPX, IONQ, ISUN, LCID, LUNA, MARK, OTCQX:MRMD, MVST, NDRA, NEPT, PLBY, POWW, PRCH, PRPO, QFIN, RKDA,...
ENGLEWOOD, CO / ACCESSWIRE / January 31, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has entered into an agreement with the Avenue Venture Opportunities Fund, L.P., an affiliate of A...
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January ...
ENGLEWOOD, CO / ACCESSWIRE / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Josh Disbrow, chief executive officer of Aytu, will present a pre-recorded company ...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...